Amrize

Amrize: Healthy End Markets And Margin Recovery Support The Upside (NYSE:AMRZ)

Deutsche Bank Cuts Price Target on Amrize to $56 From $64, Keeps Buy Rating

Amrize (AMRZ) has an average rating of overweight and mean price target of $52.87, according to anal

Amrize's 2027 Outlook Seen Improving After Weak 2026, UBS Says

Amrize's (AMRZ) 2027 period should be better than 2026, with earnings growth returning to its mid-te

UBS cuts Amrize stock price target to $42 on weak earnings outlook

Amrize (SWX:AMRZ) Stock Looks Below Fair Value After 28% Fall

Amrize shares have dropped sharply so far this year, which puts the focus squarely on whether the current price is still aligned with the cash the business is expected to generate over time. With the stock now trading well below where it started the year, the central question is how that market move lines up with the intrinsic value suggested by its cash flows. Year to date, Amrize has fallen 28.5%, which puts recent price weakness directly up against what its underlying cash flows may be...

Is Amrize (SWX:AMRZ) Undervalued As Leadership Changes Test Its Turnaround Story?

Amrize (SWX:AMRZ) is back in focus after the board appointed Mario Gross as President, Building Envelope, following Jake Gosa’s resignation and year-long notice period. Recent trading tells a cautious story. Amrize’s share price has slipped to CHF31.82, with the 30-day share price return down 11.93% and the year-to-date move down 28.49%. The 1-year total shareholder return is down 21.85%, pointing to fading momentum despite insider buying and upcoming conference exposure. See how Amrize...